Lubrizol Corp. will continue to grow its LifeSciences business, investing $60 million on new products and capacity in addition to manufacturing expansions, according to a news release.
The Wickliffe, Ohio-based specialty chemicals company, which is owned by Berkshire Hathaway, will add commercial drug product manufacturing to its particle sciences building in Bethlehem, Pa., the release stated.
That will put it next to the existing manufacturing space for development and clinical trials, which the release said will give customers a "seamless flow" through the process. This new space is expected to be operational in the fourth quarter of 2017.
The release stated that LifeSciences also will expand its global excipients — such as thermoplastic polyurethane for drug delivery systems — polymers and contract manufacturing facilities, which will affect multiple sites and increase in-house engineering capacity. This will include investments toward production of interventional catheters and longterm implantable devices, which the release described as important to the medical device segment.